Literature DB >> 2173751

Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency.

B F Thomas1, D R Compton, B R Martin.   

Abstract

delta 9-Tetrahydrocannabinol, the primary psychoactive constituent in marihuana, has been studied extensively for the last 20 years; however, the mechanisms responsible for cannabinoid activity in the central nervous system are not well understood. Although it is thought that lipophilicity plays an important role in the actions of cannabinoids, studies have not been conducted to determine whether a relationship exists between the lipophilicity and behavioral potency of cannabinoid analogs. Two procedures were used to obtain n-octanol/water partition coefficients (Po/w) of naturally occurring and synthetic cannabinoids: reverse-phase high-pressure liquid chromatographic estimation of Po/w and computer calculation of Po/w based on molecular structure. The Po/w value for delta 9-tetrahydrocannabinol obtained in this study, 9.44 x 10(6), is much greater than previously reported values obtained using shake-flask methodology, yet it is in agreement with the computer calculation based on molecular structure or molecular volume. The lipophilicity of the analogs determined in this study ranged from Po/w values of 3.92 x 10(2) to 1.93 x 10(11). All pharmacologically active cannabinoid compounds were extremely lipophilic (log Po/w values greater than 4.5). Several structural alterations were found to exert considerable influence on the lipophilicity of cannabinoid analogs. Increasing the length of the side chain in a homologous series of analogs results in an increase in lipophilicity of approximately 3-fold for each CH2 group added. Introduction of a single hydroxyl group decreased lipophilicity 3- to 40-fold, depending on the site of attachment. The behavioral potency of active analogs was not found to be correlated to lipophilicity. Therefore, data obtained in this study suggest that lipophilicity is a component, but not a primary determinant of pharmacological activity in the cannabinoids.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173751

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

1.  Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes.

Authors:  A S Bloom; W S Edgemond; J C Moldvan
Journal:  Neurochem Res       Date:  1997-05       Impact factor: 3.996

Review 2.  Efficacy in CB1 receptor-mediated signal transduction.

Authors:  Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2004-08       Impact factor: 8.739

3.  The endocannabinoid 2-arachidonoylglicerol decreases calcium induced cytochrome c release from liver mitochondria.

Authors:  Patrizia Zaccagnino; Susanna D'Oria; Luigi Luciano Romano; Almerinda Di Venere; Anna Maria Sardanelli; Michele Lorusso
Journal:  J Bioenerg Biomembr       Date:  2012-03-22       Impact factor: 2.945

4.  Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling.

Authors:  Gabriela I Patilea-Vrana; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2019-05-02       Impact factor: 3.922

5.  Differential expression of intracellular and extracellular CB(2) cannabinoid receptor protein by human peripheral blood leukocytes.

Authors:  Julie T Castaneda; Airi Harui; Sylvia M Kiertscher; Jeffrey D Roth; Michael D Roth
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-10       Impact factor: 4.147

Review 6.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine.

Authors:  Mateus M Bergamaschi; Allan Barnes; Regina H C Queiroz; Yasmin L Hurd; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-03-15       Impact factor: 4.142

8.  Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC.

Authors:  Claudine C Hunault; Tjeert T Mensinga; Irma de Vries; Hermien H Kelholt-Dijkman; Jani Hoek; Maaike Kruidenier; Marianne E C Leenders; Jan Meulenbelt
Journal:  Psychopharmacology (Berl)       Date:  2008-08-10       Impact factor: 4.530

9.  Hydroxylation and further oxidation of delta9-tetrahydrocannabinol by alkane-degrading bacteria.

Authors:  Hassan Rashidi; Muhammad T Akhtar; Frank van der Kooy; Robert Verpoorte; Wouter A Duetz
Journal:  Appl Environ Microbiol       Date:  2009-09-18       Impact factor: 4.792

10.  Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Ronald I Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.